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Determination of Adrenal Response After
Oral Administration of Multiple Doses of
Methylprednisolone
DYAL C. GARG. Ph.D.,* JOHN G. WAGNER, Ph.D.. JAMES W. AYRES. P1i.D.,** and
KENNETH S. ALBERT. Ph.D. Ann Arbor and Kalamazoo, Mich.
ORMAL cortisol production by the
adrenals has a circadian rhythm, and
many studies1-6 have shown a variation of
plasma cortisol with the time of day.
Migeon et al.7 showed that the diurnal
variation of plasma levels of 17-hydroxy-
corticosteroids in night workers and
blind persons was the same as that in
normal subjects. Hellman et al.8 showed
that cortisol was secreted intermittently
rather than continuously.
Fluorescence,9 competitive protein bind-
ing,’#{176}radioimmunoassay,11 and enzyme-
labeled immunoassay12 have all been used
to measure plasma levels of cortisol. High-
pressure liquid chromatographic (HPLC)
analysis has obtained considerable atten-
tion recently for the determination of
steroids in biologic fluids and pharmaceu-
tical products.’3-16 In our laboratory, an
HPLC assay was developed for simultane-
ous determination of both hydrocortisone
and methyiprednisolone in plasma using
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methyiprednisolone acetate as internal
standard.17
It has been documented in the litera-
ture that glucocorticoid therapy can be a
cause of adrenal insufficiency. Plasma cor-
tisol levels have been found to be low
after glucocorticoid therapy.’8”9 Using
the response of the plasma 17-hydroxycor-
ticosteroids to a 4-hour infusion of ACTH,
Christy et al.2#{176}demonstrated an impair-
ment of response in six patients who were
administered 20 to 30 mg prednisone over
a period of five to 13 days. This report
describes the results of a study designed
to ascertain the effect of multiple oral
doses of methylprednisolone on adrenal
function by measuring endogenous plasma
levels of cortisol in each of 12 normal
subjects during six days of therapy with
methyiprednisolone tablets and to evalu-
ate adrenal response after corticotropin
stimulation by measuring plasma levels of
endogenous cortisol for 24 hours after
intramuscular administration of synthetic
ACTH both before and after methyl-
prednisolone treatment.
Materials and Methods
Two treatments were administered to
12 normal male volunteers between the
ages of 19 and 29 years with body weights
from 64 to 99 kg. All subjects underwent
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a comprehensive physical examination and
provided a complete medical history
before acceptance into the study. AU
possible side effects and risks involved
were fully explained, and the subjects
signed consent forms. The clinical study
was carried out at Harris Laboratories,
Lincoln, Nebraska. Subjects selected for
the study did not receive any repository
steroid preparation during the 60 days
before the study or any other steroid
preparation including topical steroids
during the 14 days before the study. None
of the subjects was a heavy user of al-
cohol. Subjects received no other medi-
cation for seven days before the study,
and none was allowed throughout the
duration of the study. Additionally, sub-
jects did not drink alcoholic beverages
and avoided strenuous exercise. SmDking
was permitted if it was the usual habit.
The study consisted of two treatments.
Treatment A (Control)
Blood samples were collected on days 1
to 3. Sample collection started at 8:00 P.M.
on day 1 (zero time for this treatment)
and ended at 8:00 P.M. On day 3. During
the 48-hour period a total of 17 blood
samples and two urine samples were col-
lected per subject. Ten blood samples were
collected in the interval 0-24 hours (8:00
P.M. of day 1 to 8:00 P.M. of day 2), and
a 0-24 hour urine sample was collected.
Synthetic ACTH, 0.25 mg, was adminis-
tered into the upper, outer quadrant of
the right buttock at 8:00 P.M. on day 2,
i.e., 24 hours after the study started.
Seven blood samples were collected in the
interval 25-48 hours, and a 24-48 hour
(8:00 P.M. on day 2 to 8:00 P.M. on day 3)
urine sample was collected. Plasma was
separated after centrifugation and stored
at - 20#{176}Cuntil analyzed. Urine volume
was measured, and an aliquot was stored
in the freezer for analysis. There was a
one-week interval between treatments A
and B from day 3 to day 9.
Treatment B
Samples were collected on days 9
through 16, but 7:00 A.M. on day 9 was
designated “zero time” for this treat-
ment. Methylprednisolone administration
(6-a-methylprednisolone tablets, Medrol
Dosepak*) began at 7:00 A.M. (“zero
time”) on day 9 and continued according
to the schedule given in Table I until the
last tablet was given at 7:00 A.M. on day
14 (120 hours after zero time). The
ACTH (Cortrosyn**) challenge was
given at 157 hours (8:00 P.M. on day 15).
During methylprednisolone administra-
tion (0-120 hours) a total of 43 blood
samples were taken. From cessation of
administration of tablets at 120 hours and
the time of the ACTH injection, another
12 blood samples were taken (121-157
hours). Then, seven more blood samples
were taken between 158 and 181 hours,
and a 24-hour urine sample was taken
after the ACTH injection in the interval
158-181 hours. Plasma was separated
from the blood samples and frozen in
vials, properly labeled, until analyzed.
Urine volume was measured, and an ali-
quot was stored at - 20#{176}Cfor analysis.
Assay Method
A high-pressure liquid chromatographie
(HPLC) method was used for the simul-
taneous determination of both cortisol and
methylprednisolone in plasma and urine.’7
To check the day-to-day variation of the
analytical procedure, two sets of quality
control samples were prepared with the
use of human plasma. These samples were
spiked with only methylprednisolone be-
cause it was thought that the endogenous
cortisol would be sufficient to give a rea-
sonable response on the HPLC. One or
two quality control samples were run each
day the unknowns were run.
* Trademark of The Upjohn Company, Kalaina-
zoo, Mich.
** Trademark of Organon, Inc., West Orange,
N.J.
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Results and Discussion
Precision of the HPLC Method
The precision of the HPLC method was
indicated by coefficients of variation cal-
culated from two types of data. First, the
average coefficient of variation calculated
from concentrations estimated with the
use of standard curve data was 6.62%
(range 1.22 to 12.7%) for cortisol and
7.33% (range 1.53 to 12.1%) for methyl-
prednisolone. Secondly, the coefficients of
variation of the concentrations estimated
from the analysis of the quality control
samples were 4.2 and 6.0% (first set of
quality control samples analyzed over 14
days) and 4.9 and 4.1% (second set of
quality control samples analyzed over 15
days) for cortisol and methylprednisolone,
respectively.
Plasma Levels of Cortisol and
Met hyiprednisolone
Average plasma concentrations of cor-
tisol after treatment A are plotted in
Fig. 1. Average plasma cortisol and
methyiprednisolone concentrations after
treatment B are plotted in Fig. 2. The
first half of Fig. 1 gives the diurnal vari-
ation in cortisol levels over a 24-hour
period. The 0-hour (8:00 P.M.) concentra-
tion averaged 40.5 ng/ml (range 18 to
67.9 ng/ml). The 11-hour (7:00 A.M.)
average plasma concentration was 117
ng/ml (range 72.3 to 196 ng/ml). The
average plasma concentration of cortisol
in the 24-hour sample (8:00 P.M. Ofl the
second day) was 55.5 ng/ml (range 32.7
to 124 ng/ml).
Plots of individual subject concentra-
tions of cortisol (not illustrated) showed
peaks and troughs, as has been indicated
by other authors.1’3’8’2’ In this study the
sampling was not as frequent as in some
of the other studies, but with the sam-
pling schedule we used we also saw epi-
sodes of secretory activity during the
whole 24-hour interval. Average plasma
levels of cortisol as plotted in Fig. 1 do
not show as many peaks and troughs as
were seen in individual subject plots.
Intramuscular injection of ACTH at
24 hours (8:00 P.M., second day) caused
immediate stimulation of adrenocortical
function as seen by an increase in plasma
cortisol levels (Fig. 1). The average 9:00
P.M. cortisol concentration on day 1 was
36.2 ng/ml (range 13.7 to 76.6 ng/ml),
whereas the average 9:00 P.M. cortisol
concentration on day 2 was 249 ng/ml
Methyiprednisolone Dosage*
No.of
Number of 4-rn g tablets at**
7:00A.M. 12:O0noon 6:00P.M.
4-mg Total daily (Before (After (After 11:00P.M.
Day tablets dose (mg) breakfast) lunch) supper) (Bedtime)
9 6 24 2 1 1 2
10 5 20 1 1 1 2
11 4 16 1 1 1 1
12 3 12 1 1 0 1
13 2 8 1 0 0 1
14 1 4 1 0 0 0
* Twenty-one 4-mg 6-a-methylprednisolone tablets are supplied in each Medrol Dosepak.
** Meals given: breakfast, 6:30 to 7:00 A.M.; lunch, 11:30 A.M. to 12:00 noon; dinner, 5:30
to 6:00 snack, 10:30 to 11:00 P.M.
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Fig. 1. Mean plasma concentration of cortisol after tieatment A.
(range 177 to 324 ng/ml). There have
been other studies in which the effect of
ACTH administration on changes in
plasma levels or urinary levels of 17-hy-
droxycorticosteroids has been studied in
both normal and diseased states. Eik-Nes
et al.22 showed that plasma 17-hydroxycor-
ticosteroids changed from 100 ng/ml to
about 400 ng/ml after administration of
25 I.U. ACTH by infusion over 6 hours.
In a similar study, Schmidt et al. ad-
ministered 40 I.U. ACTH by infusion
over 6 hours (9:00 A.M. to 3:00 P.M.) and
found that plasma levels changed from
185 ng/ml (8:00 A.M.) to 560 ng/ml (4:00
P.M.) on day 1 and from 160 ng/ml (8:00
A.M.) to 700 ng/ml (4:00 P.M.) on day 2.
Average plasma concentrations of cor-
tisol and methylprednisolone after treat-
ment B are plotted in Fig. 2. It was found
that after one day of therapy, endogenous
cortisol declined to a limiting value of
about 10 ng/ml and remained at about
that level for five days. By the end of day
6 (about 10 hours after the last methyl-
prednisolone tablet was given), the se-
cretion of the adrenal gland tended
toward normal as evidenced by the steady
rise in serum levels of endogenous cortisol
during the interval of 130-157 hours
(normal recovery). Administration of
ACTH (0.25 mg) at 157 hours, intra-
muscularly, caused a rapid increase in
plasma cortisol concentrations.
Adrenal Response to ACTH Stimulation
Before Methyiprednisolone Treatment
Adrenalcortical response was evaluated
in two ways: (a) by calculating areas
under individual subject hydrocortisone
concentration-time curves by means of
the trapezoidal rule and obtaining the
average area; and (b) by comparing cor-
tisol concentrations 1 hour after ACTH
administration.
Trapezoidal areas (AUCo-24 hr and
AUC24_48 hr) for cortisol were calcu-
lated following treatment A, and the
areas (ng hr/ml) are given in Table II.
The ratios and differences of
AUC248 hr and A1JC024 hr were calcu-
lated, and these values are included in
Table II. For treatment A, response to
ACTH was evaluated by considering the
AUC24_48 hr versus the AUC0_24 hr since
ACTH was given at 24 hours. The mean
AUC48 hr was 2532 ng . hr/ml, while
the mean AUC0.24 hr was 2015 rig hr/nil;
the differencet in mean areas was signifi-
cant (t3.79, 0.0025>P>0.0005).
The ratios of the two areas, ATJC24_48 /
AUC-24 hr, was significantly different
I For difference in areas,
/ d’-(d)’/n
n(n_1)
where 1 is the mean difference, d is an indi-
vidual difference from one pair, and a is the
number of pairs.
For the ratio of areas,
11- RI
S.E. of B
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TABLE II
Areas Estimated by Trapezoidal Rule from Observed Cortisol Plasma





































































Mean 2015 2532 1.27* 517**
C.V. (%) 20.1 22.0 20.5 91.5
* Ratio is significantly different from unity (t = 3.59, 0.01 > F> 0.001).
** Mean difference is significant (paired * = 3.79, 0.0025 > P> 0.0005).
from unity (t = 3.59, 0.01 > P> 0.001).
The effect of ACTH on adrenal function
seemed to be instantaneous, and the effect
decreased within 3 to 4 hours after ad-
ministration.
Adrenal Response to ACTH Stimulation
After Methyiprednisolone Treatment
Trapezoidal areas (AUC13,57 hr and
AIJC,57_181 hr) were calculated for corti-
sol after treatment B, and these values
are given in Table III. The recovery of
the adrenal gland after methylpredniso-
lone treatment was quite rapid. We des-
ignated the AUC130,57 hr as a measure of
normal recovery of the adrenal gland
after multiple-dose treatments of methyl-
prednisolone and the AUC,57,8, hr as a
measure of AOTH response plus normal
recovery. The mean AUC157181 hr was
1947 ng hr/mi, while the mean AUC1SJO.
187 hr was 1495 ng hr/mi; the difference
in means was significant (t = 5.59, P <
0.005). The mean ratio of 1.34, AUC157
181 hr)/AUC1SO_157 hr, was significantly
different from unity (t = 5.06, P <
0.0005).
The average AUC130-57 hr of 1495
ng hr/mi (C.V. = 28.1%) for cortisol
after treatment B was about 74 per cent
of the average A UC024 hr of 2015 ng hr/
ml (C.V. = 20.1%) after treatment A,
indicating the fast recovery of the adrenal
gland after methylprednisolone treatment
was terminated.
Responsiveness of adrenal function to
ACTH before and after methyipredniso-
lone treatment was evaluated by compar-
ing AUC248 hr for treatment A and
AUC157_,8, hr for treatment B. The aver-
age AUC248 hr was 2532 rig hr/mi
(C.V. 22.0%), while the average
AUC,57,81 hr was 1947 ng hr/mi (C.V.
25.1%); the difference in means was sig-
TABLE m
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nificant (t = 4.71, P < 0.001). The mean
AUC157151 hr of 1947 ng hr/nil was 77
per cent of the mean AUC24_48 hr of 2532
ng hr/mi, indicating a 23 per cent re-
duction in area attributable to multiple-
dose administration of methylpredniso-
lone.
Since ACTH was administered at 8:00
P.M. in both treatments, comparison of
plasma cortisol concentrations in 9:00 P.M.
samples was made as a measure of re-
sponsiveness to ACTH both before and
after methylprednisolone treatment. The
plasma cortisol levels are listed in Table
IV. The paired t for cortisol levels after
ACTH (25 hours) and those before
AOTH (1 hour) after treatment A was
23.8 (P <0.0005). The paired t for cor-
tisol levels in 158-hour samples after
treatment B and those in 25-hour sam-
ples after treatment A was 9.56 (P <
0.0005). This was in agreement with the
comparison of areas.
Urinary Data
The quality of the urinary data was
not nearly as good as that of the plasma
concentration data because of interfering
peaks in the HPLC tracings from urine
samples. The amounts of unconjugated
cortisol (pg) excreted in three intervals
are presented in Table V. After treat-
ment A, the mean amount of cortisol ex-
creted in the 0-24 hour period was 39.4
g, while in the 24-48 hour period the
mean amount excreted was 86.6 pg; the
difference in the means was significant
(t = 4.72, P <0.005). The mean amount
Areas Estimated by Trapezoidal Rule from Observed Cortisol Plasma
Concentrations for Treatment B
AUC (ng. hr/mi)











1 817 1229 1.50 412
2 1448 1958 1.35 510
3 1573 1724 1.10 151
4 2152 2212 1.03 61
5 1729 2769 1.60 1040
6 1287 1646 1.28 359
7 790 1470 1.86 680
8 1830 2644 1.44 813
9 1635 2006 1.23 371
10 1988 2428 1.22 440
11 1240 1428 1.15 188
12 1445 1854 1.28 409
Mean 1495 1947 1.34* 453**
C.V. (%) 28.1 25.1 17.4 61.8
* Ratio is significantly different from unity (* = 5.055, P < 0.0005).
** Mean difference is significant (paired * = 5.59, P < 0.005).
ADRENAL RESPONSE TO METHYLPREDNISOLONE
TABLE IV
Plasma Cortisol Concentrations (ng/mI) in
11:00 P.M. Samples Before and After
ACTE Injection
Subject
Treatme nt A Treatment B
After ACTHBefore ACTH After ACTH
no. (lhr) (25hr) (158hr)
1 24.7 212 96.4
2 34.7 215 157
3 33.4 250 166
4 45.2 291 195
5 76.6 324 D1
6 29.5 177 151
7 21.0 255 129
8 46.5 239 174
9 45.2 270 179
10 38.6 262 146
11 25.1 272 125
12 13.7 222 133
Mean 36.2* 249*t 154t
C.V. (%) 45.2 15.7 19.1
* Paired * = 23.8 (P < 0.0005).
t Paired * = 9.56 (P < 0.0005).
excreted in the 157-181 hour period after Treatment B:
treatment B was 61.0 pg; this mean dif.. amount excreted
fered significantly from the mean of 39.4 renal clearance = 157-181 hr (pg) <
&g in the 0-24 hour period (t = 2.76, AUC157_181 hr
0.01 > P > 0.005) and also from the (ng’ hr/mi)
mean of 86.6 g for the 24-48 hour pe- = = 0.52 mi/mm
nod (t = 2.90, 0.01 > P > 0.005). 60 1947 60
The renal clearances of cortisol esti-
mated from the post-ACTH data for both Methylprednisolone Pharmacolcinetws
treatment A and B agree well based on The apparent elimination rate con-
the mean data as shown below: stants from fall-off curves of methyl-
prednisolone plasma concentration with
Treatment A: time after the first, second, third, fourth,
amount excreted 13th, 14th, 15th, and 18th doses for each
24-48 hr (JIg) x subject were calculated. The overall mean
renal clearance =
AUC248 hr apparent elimination rate constant was
(ng hr/mi) 0.213 hr, which corresponds to a half-
X = 0.57 mi/mm life of 3.25 hours. This value for the half-
60 2532 60 life is very close to the 3.13 hours re-
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ported by Jenkins and Schemmel.24
Stjernhohn and Katz25 reported a value
of 2.75 ± 0.82 hours. Slaunwhite and
Sandberg2#{176} reported the much shorter
value of 1.3 hours after administration of
‘4C-6-a-methylprednisolone intravenously
to humans.
Trends in the magnitudes of the aver-
age (apparent elimination rate con-
stant) values with dose number were in-
vestigated. If there was enzyme induc-
tion, one would expect the fi value to in-
crease with increase in the dose number.
If there was no enzyme induction, one
would expect fi not to be related to the
dose number. There was no evidence of
enzyme induction of metabolism of meth-
yiprednisolone since the mean apparent
elimination rate constant of the 12 sub-
jects was not significantly correlated with
the dose number (r = - 0.246, P> 0.25).
TABLE V





(157-l8lhr)0-24 hr 24-48 hr
1 19.8 28.1 21.8
2 31.0 98.6 32.0
3 31.0 60.2 49.2
4 22.1 120.8 61.5
5 32.4 38.9 33.6
6 35.5 66.6 66.2
7 45.3 93.3 48.4
8 48.6 129.7 143
9 25.9 96.9 64.0
10 73.1 164 89.8
11 46.5 84.5 50.8
12 62.0 57.8 71.1
Mean 39 4* ** 86.6*t 61.Ot**
S.D. 16.2 39.2 31.9
C.V. (%) 41.1 45.3 52.3
* Paired * = 4.723 (P <0.0005).
t Paired t 2.902 (0.005 <P < 0.001).
** Paired * 2.759 (0.005 < P < 0.01).
Snrnim’.ry
The effect of multiple oral doses of
methyiprednisolone on adrenal function
was ascertained by measuring endoge-
nous plasma levels of cortisol in each of
12 normal subjects during six days of
progressively diminishing therapy with
methylprednisolone tablets (4 mg each).
Adrenal response was also evaluated after
corticotropin stimulation by measuring
plasma levels of endogenous cortisol for
24 hours after intramuscular administra-
tion of synthetic ACTH both before and
after the start of the methyiprednisolone
treatment. It was found that after one
day of methylprednisolone therapy, en-
dogenous cortisol declined to a limiting
value of about 10 ng/ml and remained at
about that level for five days. About 10
hours after the last methylprednisoione
tablet was given, the secretion of the
adrenal gland tended toward normal as
evidenced by the steady rise in plasma
levels of endogenous cortisol during day
7. This conclusion is supported by results
of the ACTH challenge, which showed
that the area under the cortisol concen-
tration-time curve through 24 hours was
reduced by only 23 per cent after termi-
nation of methylprednisolone therapy.
There was no evidence that methyipred-
nisolone induced its own metabolism since
the mean apparent elimination rate con-
stant was not significantly correlated with
dose. The overall average elimination rate
constant was 0.213 hr’, corresponding to
a half-life of 3.25 hours.
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